TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06579430
Drug: Indocyanine Green near infrared fluorescence imaging
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
Study: NCT06579430
Drug: Indocyanine Green near infrared fluorescence imaging
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL
Study: NCT06107790
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg
Study: NCT02812615
Drug: Albendazole/Pyrantel Pamoate
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
Study: NCT03192176
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT02058017
Drug: OPB-51602
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03345173
Drug: CI-581-a
Normalized name: 13-cis-Vitamin A acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two infusions in the context of naltrexone induction protocol.
Study: NCT03345173
Drug: CI-581-b
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions in the context of naltrexone induction protocol.
Study: NCT02003768
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
Study: NCT02003768
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
Study: NCT02076243
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
Study: NCT00002590
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002590
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04484935
Drug: Nirsevimab
Normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Study: NCT00003251
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003251
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003251
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04806529
Drug: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)
Normalized name: SARS-CoV-2 Sclamp adjuvanted vaccine
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
Study: NCT02742519
Drug: ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01381471
Drug: fluticasone propionate/salmeterol xinafoate combination
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate/salmeterol xinafoate combination
Study: NCT02178098
Drug: ETC-1002
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 capsules taken once daily
Study: NCT00088413
Drug: Sargramostim (GM-CSF, Leukine)
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
Study: NCT00957242
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
Study: NCT00584246
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 - 150 mg po qhs for 2 months
Study: NCT00154076
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
Study: NCT00154076
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
Study: NCT00002590
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01044303
Drug: Myfortic Escalation
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
Study: NCT00002590
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002590
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01519037
Drug: Cinacalcet 60 MG
Normalized name: cinacalcet 60 MG
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one dose of oral cinacalcet, 60mg
Study: NCT00002590
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002590
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122070
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage can vary from 50 to 150 mg at PI's discretion
Study: NCT00417833
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04396327
Drug: SM-1
Normalized name: SM-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphenhydramine, zolpidem and lorazepam
Study: NCT04396327
Drug: Active Comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphenhydramine and lorazepam
Study: NCT06189027
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive administration of MDMA to assist psychotherapeutic process
Study: NCT01553058
Drug: Adalimumab (Humira)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
Study: NCT00025324
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025324
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025324
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02759016
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02759016
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of Care
Study: NCT00809497
Drug: Propionyl-L-carnitine Tablets
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg tablets, oral administration of 2g daily
Study: NCT00031694
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00031694
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00563446
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02009215
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
Study: NCT00352976
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
Study: NCT00352976
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
Study: NCT00352976
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
Study: NCT01093820
Drug: methoxy-polyethyleneglycol epoetin beta
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
Study: NCT00418613
Drug: MK633
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MK0633 100mg capsules qd for a 12-wk treatment period.
Study: NCT00967434
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
Study: NCT03973567
Drug: selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
Study: NCT00967434
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
Study: NCT03498196
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
Study: NCT02529852
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I.
Study: NCT02529852
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
Study: NCT02529852
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
Study: NCT02529852
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
Study: NCT03532542
Drug: Casimersen
Normalized name: Casimersen
DrugBank: Casimersen (DB14984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Casimersen solution for IV infusion
Study: NCT01923012
Drug: Vitamin K2 (Menaquinone)
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01708915
Drug: nicoboxil
Normalized name: nicoboxil
DrugBank: Nicoboxil (DB12911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
Study: NCT01708915
Drug: placebo matching nonivamide + nicoboxil
Normalized name: nicoboxil
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
Study: NCT01708915
Drug: nonivamide + nicoboxil (Finalgon)
Normalized name: nicoboxil
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
Study: NCT01708915
Drug: nonivamide
Normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
Study: NCT03935594
Drug: Saline Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
Study: NCT03532542
Drug: Golodirsen
Normalized name: golodirsen
DrugBank: Golodirsen (DB15593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Golodirsen solution for IV infusion
Study: NCT00877227
Drug: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)
Normalized name: 5-formyltetrahydrofolic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
Study: NCT03196973
Drug: DF289
Normalized name: Dexamethasone Furoate 289
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vial into the affected ear twice daily for 7 days
Study: NCT03196973
Drug: DF277
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 vial into the affected ear twice daily for 7 days
Study: NCT00802880
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00408772
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00112840
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
Study: NCT03826316
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetic study under fasting conditions
Study: NCT01641341
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day for seven to eight weeks
Study: NCT01641341
Drug: Pancrelipase
Normalized name: pancrelipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase (one capsule prior to meals or snacks)
Study: NCT01641341
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (500mg twice a day for 7 days)
Study: NCT03305913
Drug: TAS 102
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 tablet
Study: NCT03305913
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib tablet
Study: NCT00641745
Drug: Lurasidone HCl
Normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 - 120mg per day
Study: NCT00641745
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone
Study: NCT01758172
Drug: 6% hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01758172
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01453686
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
Study: NCT01453686
Drug: Clobetasol Propionate 0.05%
Normalized name: CLOBETASOL PROPIONATE 0.05% OINT
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
Study: NCT00001302
Drug: PSC 833
Normalized name: PSC-04
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00490802
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin
Study: NCT01186159
Drug: Parecoxib Sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
Study: NCT00459212
Drug: GTI-2040
Normalized name: GTI-2040
DrugBank: GTI-2040 (DB15030)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04012294
Drug: Allopurinol Pill
Normalized name: allopurinol Pill
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant.
Study: NCT00369408
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
Study: NCT02394028
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab will be administered as per regimen specified in individual arms.